Information about Kinesitherapie PS - PelviPrima
My details
*
*
*

Kinesitherapie PS - PelviPrima (SRL)

Company information

Status
Active

Enterprise number

BE1008.235.915

VAT liability
No
Established
10-04-2024
Last balance sheet year
2024
Company size
Micro 0 FTE
Principal activity
Combined office administrative service activities
Health barometer
Credit limit
Detailpage

Are you looking for more information about this company?

  • Consult health at a glance

  • Choose quick insights or granular details

  • Get updates on important developments

7-day free trial, no credit card required.

Financial data from Kinesitherapie PS - PelviPrima

2024
Profit/Loss 6,301
Equity 8,701
Gross margin 9,209

Publications from Kinesitherapie PS - PelviPrima

Date Publication
12-04-2024 Rubric Constitution (New Juridical Person, Opening Branch, etc...) (NL)

Frequently asked questions

What is the enterprise number of Kinesitherapie PS - PelviPrima?
The enterprise number of Kinesitherapie PS - PelviPrima is BE 1008.235.915.
Wat is the PEPPOL ID of Kinesitherapie PS - PelviPrima?
The PEPPOL ID of Kinesitherapie PS - PelviPrima is 0208:1008235915. Log in or start a free trial to see the full overview.
When was Kinesitherapie PS - PelviPrima founded?
Kinesitherapie PS - PelviPrima was founded on 10-04-2024.
What is the address of Kinesitherapie PS - PelviPrima?
The current registered office of Kinesitherapie PS - PelviPrima is located at Gouwelozestraat 18, 8400 Oostende.
When was the last time Kinesitherapie PS - PelviPrima filed their annual financial statements?
The most recent financial statements of Kinesitherapie PS - PelviPrima were filed on 31-07-2025.
How many employees does Kinesitherapie PS - PelviPrima have?
There are currently no employees working at Kinesitherapie PS - PelviPrima or no workforce information is available.
What is the annual turnover of Kinesitherapie PS - PelviPrima?
At the time of its most recent financial statements, Kinesitherapie PS - PelviPrima did not publish any turnover figures. Kinesitherapie PS - PelviPrima reported a gross margin of €9,208.50.